Showing results (71-80 of 107) with videos related to
Sort By:
Pageof 11
Neuropsychiatric Disease and Treatment|June 28, 2023
Psychometrics of the Concise Health Risk Tracking Self-Report (CHRT-SR16) Assessment of Suicidality in a Sample of Adults with Moderate to Severe Methamphetamine Use Disorder: Findings from the ADAPT-2 Randomized TrialJoseph M Trombello, Alexandra Kulikova, Taryn L Mayes, et al.Journal of Substance Use and Addiction Treatment|February 23, 2023
Naltrexone plus bupropion reduces cigarette smoking in individuals with methamphetamine use disorder: A secondary analysis from the CTN ADAPT-2 trialJoy M Schmitz, Angela L Stotts, Jin H Yoon, et al.Journal of Psychiatric Research|May 16, 2020
Predicting future suicidal events in adolescents using the Concise Health Risk Tracking Self-Report (CHRT-SR)Taryn L Mayes, Michael Killian, A John Rush, et al.Journal of Affective Disorders|April 13, 2018
Psychometric properties of the concise health risk tracking (CHRT) in adolescents with suicidalityTaryn L Mayes, Betsy D Kennard, Michael Killian, et al.The Journal of Clinical Psychiatry|August 6, 2025
Early Change in Depressive Symptom Severity With Naltrexone-Bupropion Combination and Its Association With Reduction in Methamphetamine Use in ADAPT-2 TrialManish K Jha, Udi E Ghitza, Steve Shoptaw, et al.Psychiatry Research|June 26, 2023
Predicting suicidal events: A comparison of the Concise Health Risk Tracking Self-Report (CHRT-SR) and the Columbia Suicide Severity Rating Scale (C-SSRS)Taryn L Mayes, Thomas Carmody, A John Rush, et al.The Journal of Clinical Psychiatry|December 21, 2023
A Comparison of Depressive Symptom Self-Reported Measures in the Texas Youth Depression and Suicide Research Network (TX-YDSRN)Karabi Nandy, A John Rush, Thomas Carmody, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 5, 2025
Towards causal inference-based antidepressant selection with brain and blood biomarkersMilica Barac, Caroline W Grant, Russell Toll, et al.Journal of Addiction Medicine|July 7, 2025
Craving, Impulsivity, and Subsequent Methamphetamine Use With Naltrexone-Bupropion Versus Placebo: Findings From a Randomized Clinical TrialManish K Jha, Udi E Ghitza, Thomas Carmody, et al.Contemporary Clinical Trials|May 13, 2025
Randomized, placebo-controlled trial of injectable extended-release naltrexone and injectable extended-release buprenorphine for cocaine use disorder (CURB-2): Study rationale and designMadhukar H Trivedi, Mariah M Kalmin, Thomas Carmody, et al.Pageof 11